Subcutaneous Fondaparinux in the Initial Treatment of Venous Thromboembolism

42 Japanese patients with acute venous thromboembolism (symptomatic acute pulmonary embolism, symptomatic acute deep vein thrombosis, or asymptomatic acute deep vein thrombosis with proximal thrombus), mean age 64.6 years, 50% male.

Subcutaneous fondaparinux (5.0 mg or 7.5 mg once daily, adjusted according to body weight, age, and creatinine clearance) until PT-INR > 1.5, followed by at least 3 months of warfarin.

Recurrence of symptomatic venous thromboembolism and bleeding events (major and minor) during the observation period (at least 3 months).hard clinical